(Q35212552)

7 August 2017

1 reference

title

Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

1 reference

Amir F Ayyobi

1

1 reference

PubMed ID

12957324

7 August 2017

John D Brunzell

series ordinal

2

1 reference

PubMed ID

12957324

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

4A

1 reference

7 August 2017

27J-33J

1 reference

Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Relation of body fat distribution to metabolic complications of obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

The visceral adiposity syndrome in Japanese-American men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Relationship of fat distribution to glucose tolerance. Results of computed tomography in male participants of the Normative Aging Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

INTERRELATIONSHIP BETWEEN SKINFOLD THICKNESS, SERUM LIPIDS AND BLOOD SUGAR IN NORMAL MEN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Weight gain and serum triglycerides in normal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Serum triglycerides in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Features of syndrome X in first-degree relatives of NIDDM patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Myocardial infarction in the familial forms of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

LDL physical and chemical properties in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: Normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Novel genes for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

LDL particle size distribution. Results from the Framingham Offspring Study

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

7 January 2021

Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Low-density lipoprotein size, pravastatin treatment, and coronary events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Effect of hepatic lipase on LDL in normal men and those with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Hepatic lipase as a focal point for the development and treatment of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Substrate delivery as a determinant of hepatic apoB secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

7 January 2021

Familial combined hyperlipidemia and abnormal lipoprotein lipase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

7 January 2021

New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900613-1

7 January 2021

10.1016/S0002-9149(03)00613-1

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12957324